Shots:

• The company received the MHRA’s approval to initiate a FIH P-I HV trial of VS-041 (oral) for the potential treatment of heart failure with preserved ejection fraction (HFpEF)
• This P-I study will evaluate the safety, tolerability & PK of VS-041 in healthy volunteers, alongside Vasa also received a $11M seed funding led by Orphinic Scientific, i&i Biotech Fund among others
• Preclinical study co-funded by the ERDF & Polish NCRD showed, VS-041 significantly reduced cardiac fibrosis and improved diastolic heart function, preventing the release of endotrophin from primary human cardiac fibroblasts. During GLP toxicology assessments, it exhibited significant safety & tolerability.

Ref: Vasa Therapeutics | Image: Vasa Therapeutics

Related news:- Novo Nordisk Reports P-III Trial (STEP-HFpEF) Results of Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com